Highest-materiality recent filing
AnaptysBio subleases 45,057 sq ft of HQ to First Tracks for up to ~22 months
Sublease of 45,057 rentable sq ft at 10770 Wateridge Circle, San Diego, for 12-month initial term starting June 15, 2026.
AnaptysBio files Form 8937 with IRS regarding tax treatment of First Tracks spin-off dividend
Filed Form 8937 with IRS concerning dividend from separation and spin-off of First Tracks Biotherapeutics.
AnaptysBio changes fiscal year-end from Dec 31 to June 30, effective July 1, 2026
Board approved fiscal year change from December 31 to June 30, effective July 1, 2026.
AnaptysBio Q1 net loss $52.9M; completes First Tracks spin-off, Jemperli royalties up 44%
Net loss per share $1.84 vs $1.28 YoY; collaboration revenue $25.6M (Jemperli royalties $24.7M, +44%).
AnaptysBio appoints Christopher Murphy CFO ($42,917/mo) and Owen Hughes to board
Christopher Murphy appointed CFO effective May 11, 2026; previously CFO at Third Harmonic Bio and Horizon Therapeutics.
AnaptysBio pro forma continuing ops net income $114.9M after First Tracks spin-off
Pro forma continuing ops net income $114.9M for FY2025; basic EPS $3.99, diluted $3.07.
Each ANAB shareholder received one TRAX share for each share held on record date April 6, 2026.
AnaptysBio approves spin-off of First Tracks Biotherapeutics; distribution set for April 20, 2026
Anaptys stockholders to receive one share of First Tracks Bio (TRAX) per ANAB share held on April 6, 2026; distribution expected pre-market April 20, 2026.
AnaptysBio plans spin-off of biopharma as First Tracks (TRAX); Q4 net income $49.6M
Spin-off of biopharma portfolio into First Tracks Biotherapeutics (TRAX) on track for Q2 2026, potentially late April.
AnaptysBio reports preliminary cash & investments of ~$310M as of Dec 31, 2025
Preliminary unaudited cash, equivalents and investments ~$310M as of Dec 31, 2025.
AnaptysBio sues Tesaro and GSK for breach of collaboration agreement on dostarlimab
AnaptysBio filed suit in Delaware Chancery Court on Nov 20, 2025, alleging material breach of the Collaboration Agreement by Tesaro and GSK.
AnaptysBio sues Tesaro and GSK for breach of Jemperli collaboration; countersuit filed
AnaptysBio alleges Tesaro breached exclusivity by conducting trials with competing PD-1 antagonists (e.g., Keytruda) and failing to maximize Jemperli return.
Board authorizes $100M increase in stock repurchase plan; $106.4M total capacity
Board amended Stock Repurchase Plan to allow up to $100M additional repurchases, plus $6.4M remaining under prior $75M plan.
AnaptysBio's rosnilimab fails Phase 2 UC trial; trial discontinued
Rosnilimab did not meet primary (mMS change) or key secondary endpoints at Week 12 in moderate-to-severe UC.
AnaptysBio plans to separate biopharma ops from royalty assets by YE 2026; Q3 net income $15.1M
Intent to split into two public companies, one holding Jemperli royalties and milestones, the other advancing pipeline assets.
AnaptysBio holds ANB033 (CD122 antagonist) investor event; updates corporate presentation
Conference call and slide presentation on ANB033 (CD122 antagonist) held on October 14, 2025.
AnaptysBio to split into two public companies by end of 2026; royalty assets separate from biopharma
CEO Daniel Faga expected to lead Biopharma Co; Royalty Co holds Jemperli (GSK) and imsidolimab (Vanda) royalties.
AnaptysBio Q2 net loss narrows to $38.6M; rosnilimab Phase 2b RA data positive
Net loss $38.6M ($1.34/sh) vs $46.7M ($1.71) YoY; collaboration revenue $22.3M, up from $11.0M.
AnaptysBio shareholders approve amended equity plan, elect directors at 2025 annual meeting
Elected Rita Jain, John Orwin, and J. Anthony Ware as Class II directors for three-year terms with over 21M votes for each.
AnaptysBio rosnilimab Phase 2b RA data shows best-in-disease profile with JAK-like efficacy
424-patient Phase 2b trial: rosnilimab achieved JAK-like efficacy on CDAI LDA, remission, and ACR70 through six months.
Cash and investments $383M as of March 31, 2025, with cash runway through year-end 2027.
AnaptysBio authorizes up to $75M stock repurchase plan
Board authorized $75M buyback of outstanding common stock.
AnaptysBio reports positive rosnilimab RA data; Q4 net loss narrows to $21.8M; cash $420.8M
Rosnilimab achieved statistical significance on primary endpoint (DAS28-CRP) at Week 12 in Phase 2b RA trial; highest-ever CDAI LDA responses reported.
AnaptysBio updates corporate investor presentation; details not available from filing
Filing indicates updated February 2025 corporate presentation, but full content not provided in extract.
Phase 2b RENOIR trial (n=424) met primary endpoint (mean DAS-28 CRP change at week 12) across all three doses vs placebo (p<0.01).
AnaptysBio licenses imsidolimab to Vanda for $15M upfront; BLA/MAA prep underway
Anaptys receives $10M upfront and $5M for drug supply; eligible for up to $35M in milestones and 10% royalty on net sales.
AnaptysBio Phase 2B trial of ANB032 fails endpoints in atopic dermatitis; cash ~$415M
ANB032 did not meet primary endpoint EASI-75 or any secondary endpoints at Week 14 in 201-patient ARISE-AD trial.
AnaptysBio Q3 net loss $1.14/shr; cash $458M; Phase 2b data catalysts ahead
Net loss $32.9M ($1.14/shr) vs $37.3M ($1.41/shr) year-ago; nine-month loss $4.46/shr.
AnaptysBio prices public offering of 2.75M shares at $36.50 for ~$100M gross
Gross proceeds ~$100M from sale of 2,750,498 shares at $36.50 per share.
AnaptysBio Q2 net loss $46.7M; cash $393.5M; ANB032 Phase 2b enrollment complete, data Dec 2024
Net loss of $46.7M ($1.71 per share) for Q2 2024, vs $39.8M loss ($1.50) in Q2 2023.
Daniel Faga, Dennis Fenton, and Oleg Nodelman elected as Class I directors with 22.3M, 21.9M, and 18.8M votes for, respectively.
Q1 2024 net loss $43.9M ($1.64/share) vs $44.3M ($1.58/share) in Q1 2023; revenue $7.2M from Jemperli royalties.
AnaptysBio reports Q4 2023 net loss of $42.2M, cash $417.9M; pipeline on track
Q4 net loss $42.2M ($1.59 per share); full-year net loss $163.6M ($6.08 per share).
AnaptysBio expects $417M cash at year-end 2023; presents at JPM Healthcare Conference
Preliminary cash, cash equivalents, and investments of approximately $417M as of December 31, 2023.
Upfront cash payment of $7M ($4M license fee + $3M for GMP supply of ANB101).
AnaptysBio Q3 net loss $37.3M ($1.41/sh); imsidolimab Phase 3 GPP hits primary endpoint
Net loss $37.3M ($1.41/sh) vs $33.5M ($1.18/sh) YoY; R&D spend rose to $30.9M.
AnaptysBio presents R&D slide deck on PD-1 agonist rosnilimab
Presented rosnilimab (PD-1 agonist) R&D slide presentation on October 25, 2023.
53.3% of imsidolimab-treated patients achieved GPPPGA 0/1 at Week 4 vs 13.3% placebo (p=0.0131).
AnaptysBio Chairman James Topper resigns; John Orwin named Chairman
James Topper resigned as Class II director and Chairman effective Sept 15, 2023; no disagreement with company.
AnaptysBio Q2 net loss $39.8M; imsidolimab Phase 3 enrollment complete
Q2 net loss $39.8M ($1.50/sh) vs $32.6M ($1.15) YoY; six-month loss $84.1M ($3.08/sh).
AnaptysBio shareholders elect three directors, ratify KPMG, approve executive pay, and amend charter
Elected Magda Marquet (21.6M for), Hollings Renton (16.9M for), John P. Schmid (20.4M for) as Class III directors for three-year terms.
AnaptysBio reports Q1 net loss of $44.3M; initiates Phase 2b for ANB032 in atopic dermatitis
Net loss of $44.3M ($1.58 per share) vs $36.3M loss in Q1 2022; R&D expenses rose to $35.0M.
AnaptysBio director Laura Hamill resigns; Rita Jain appointed to board and compensation committee
Laura J. Hamill resigned as Class II director effective April 1, 2023; no disagreement with company.
Net loss for Q4 2022 was $26.4M ($0.93 per share); full year net loss $128.7M ($4.57 per share), compared to $57.8M in 2021.
AnaptysBio adopts amended bylaws to align with DGCL changes and universal proxy rules
Board approved Second Amended and Restated Bylaws effective Feb 7, 2023; updates advance notice, proxy procedures, and exclusive forum clause.
AnaptysBio authorizes $50M stock repurchase plan; cash >$575M
Board authorized repurchase of up to $50M of common stock through Dec 31, 2023.
AnaptysBio ends alopecia areata trial; launches Phase 2b for RA and atopic dermatitis
Rosnilimab Phase 2a in alopecia areata failed to achieve target efficacy (no patient SALT<20); further development discontinued.
AnaptysBio Q3 net loss $33.5M ($1.18/sh); cash $590.5M; alopecia areata data Q1 2023
Net loss $33.5M (Q3 2022) vs $6.7M (Q3 2021); loss/share $1.18 vs $0.24.
AnaptysBio sells Zejula royalty rights to DRI Healthcare for $35M upfront
Received $35M upfront from DRI for all future Zejula royalties from GSK (effective July 2022).
Imsidolimab HARP Phase 2 fails to beat placebo in hidradenitis suppurativa; HS development halted
Imsidolimab did not improve primary endpoint (AN count change) or HiSCR50 vs placebo at Week 16 in moderate-to-severe HS.
On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026.
On September 15, 2023, the Board appointed John Orwin as a Class II director, a member of the Nominating and Corporate Governance Committee and Chairman of the Board, effective immediately.
On September 14, 2023, James N. Topper, M.D., Ph.D., advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that he would resign as a Class II director and as Chairman of the Board, effective on September 15, 2023.
On April 3, 2023, the Board appointed Rita Jain, M.D. as a Class II director and as a member of the Compensation Committee, effective immediately.
On April 1, 2023, Laura J. Hamill advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that she would resign as a Class II director of the Board, effective on April 1, 2023 (the “ Resignation ”).
the Company appointed Daniel Faga, a Class I director of the Board, to serve as Interim President and Chief Executive Officer of the Company, effective as of March 21, 2022.
On March 20, 2022, Hamza Suria, provided notice to the board of directors (the “Board”) of AnaptysBio, Inc. (the “Company”) of his resignation as President and Chief Executive Officer and as a Class II director of the Company, effective immediately.
On November 26, 2021, AnaptysBio, Inc. (the “Company”) appointed Mr. Daniel Faga, as a Class I director on its board of directors (the “Board”), effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material